Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer is one of the most unappreciated stocks in its industry and the low price shows. Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share. Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies. On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00. It's ready for a move up any day. Long!
NYSE:PFELong
by HotCharts
PFIZER SHORT Trading PlanEU states back spending up to $2.7 billion upfront on COVID-19 vaccines however,EU officials said the bloc would not buy vaccines produced exclusively in the United States, which includes PFIZER, fearing that would delay supplies to Europe. Hence, I expect the share price will dip further. Key Trading Plan: i) SHORT when it reaches the pull back price at 34.98 and it breaks support level at 32.87 before reaching target Take Profit point at 28.28. ii) LONG when the price breaks the resistance level of 36.89 with the target Take Profit point at 39.33 Author: S.I.D. Aizu
NYSE:PFEShort
by SIDCapital
Pfizer: PFE. Hardly any downside. Perfect Entry.The bad news with Pfizer's clinical trial is great news for traders and investors. Why? Because the 'bottom' has been gauged by this piece of over the weekend news. The bad news does not materially affect existing revenue stream and earnings. The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news before market open. Anyone who wanted and NEEDED to sell has mostly sold, and there was no lack of buyers to take those orders at the $35.50. Perfect opportunity for a long trade, short term or long. Anything above 34.50 is a BUY. Interval Targets are the Fibonacci levels on the chart. Final target: $45
NYSE:PFELong
by yujingr
5 Stocks we are looking into for the Covid-19 VaccineFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect something like this to go down. As far as stocks such as Pfizer, Pfizer so far is greatly underrated in terms of growth potential during the vaccine trials period, and likely because of that it is due for a bullish run quite soon. NVAX and Moderna, I believe already have the most stable growth potential given the logarithmic curves. These 5 stocks may be quite interesting to look at given all these giants from Pfizer to Moderna to Gilead are working on being the forefront of the expected Covid19 vaccine delivery. If this is a huge revenue booster, that means obvious profit turn over potential. Also, it is likely better for a buy entry previous to August, September, and the winter when hype may start increasing. Lots of the excitement have very recently slowed down, and you likely don't want to wait for the hype if you do long term holds.
NYSE:PFELong
by gamer456148
1
PFE Is A Value StockPfizer has maintained the same amount of revenues since 2010 which actually means it’s shrinking a bit (inflation) but this stock has a lot of value to offer. Their annual EPS is $2.80 and they pay out an annual dividend of $1.52 (4% yield) of which increases 16c every year. They have a healthy and steady Cash Flow of $4.20 and their shares outstanding have decreased at a 2-3% rate every year. Pfizer is a Pharmaceutical company that develops and markets medicine for humans and animals valued at 200Bn
NYSE:PFELong
by BlueFlamingo